A total of 85 cases were included. Average age was 54 years (range 29-82). Mean tumor size was 21.45 ± 9.55 mm, clinically positive axillary nodes in 36 patients

Relative expression of each isoform was 2.33 for B1, 2.95 for B2, 0.406 for B3, 1.65 for B4, 4.14 for B5 and 0.69 for B6.

At 48 months, 10 recurrences occurred: two local, three locoregional and five distant, with five deaths. Disease-free period was 45 ± 12 months, with an overall survival of 57.5 ± 9.6 months.

Conclusion: isoforms that showed higher expression were B1, B2 and B5. It is important to note isoform B5 was highly expressed in HER-2 overexpressed and triple negative profile.

**Results**

A total of 85 cases were included. Average age was 54 years (range 29-82). Mean tumor size was 21.45 ± 9.55 mm, clinically positive axillary nodes in 36 patients (36/85); pathologic stage IIA, IIB 15, and IIIA in 7 cases. Invasive ductal carcinoma was present in 76/85 cases, high grade tumors was present in 37/85 cases.

Estrogen receptor was positive in 83% (71/85) and progesterone in 62% (53/85). Her2 was positive in 20% (17/85) and 12 cases were triple negative (14%).

Isoforms of estrogen receptor beta were: 31 for B1 (36%), 51 for B2 (60%), 15 for B3 (17.6%), 26 for B4 (30.5%), 55 for B5 (64.7%) and 6 for B6 (5.8%).

Relative expression of each isoform was 2.33 for B1, 2.95 for B2, 0.406 for B3, 1.65 for B4, 4.14 for B5 and 0.69 for B6.

At 48 months, 10 recurrences occurred: two local, three locoregional and five distant, with five deaths. Disease-free period was 45 ± 12 months, with an overall survival of 57.5 ± 9.6 months.

**Conclusions**

This finding will allow the intentional search by immunohistochemistry of these isoforms, and lays the foundations for future studies that could evaluate the prognostic and/or predictive roles of the presence of isoforms B1, B2, and B5; and the low expression of B3, B4, and B6.